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Abstract:	Fleischer,	Justin				Caveolin	Binding	Motif	Mutation	Yields	a	Variance	in	Follicle	Stimulating	Hormone	Receptor	Signaling		Advisor:	Brian	D.	Cohen	The	human	follicle	stimulating	hormone	receptor	(hFSHR)	is	a	glycoprotein	hormone	receptor	belonging	to	the	g	protein-coupled	receptor	family.	It	is	important	in	both	male	and	female	reproductive	processes;	defects	in	hFSHR	can	lead	to	infertility,	delayed	puberty,	reduced	muscle	bulk,	and	osteoporosis.	Work	in	other	labs	has	shown	that	GPCRs	can	be	localized	to	microdomains	located	within	the	cell	membrane	called	lipid	rafts.	These	regions	are	highly	resistant	to	detergents	because	of	the	high	concentration	of	sphingolipids	and	cholesterol.	Also	within	these	domains,	an	intracellular	protein,	caveolin,	is	present.	Our	lab	has	shown	that	hFSHR	also	localizes	to	lipid	raft	domains.	We	hypothesize	that	interaction	with	caveolin	is	important	in	the	raft	residency	of	hFSHR	through	a	putative	caveolin	binding	motif	(CBM).	The	interaction	between	caveolin	and	hFSHR	in	these	microdomains	may	regulate	intracellular	pathways	activated	by	the	receptor.		To	test	our	hypothesis,	we	have	constructed	CBM	mutants	and	are	in	the	process	of	creating	stable	cell	lines	expressing	the	mutant	receptors	to	study	the	effects	of	mutating	the	key	phenylalanine	residues	of	the	CBM.		Interestingly,	wild	type	FSHR	presents	as	a	doublet	on	a	western	blot	while	the	479L	only	have	a	single	band.	We	theorize	that	one	of	these	bands	may	be	a	glycosylation	variant	however	further	investigation	is	required.	The	mutated	receptors	qualitatively	show	normal	p44-MAPK	signaling	in	response	to	FSH,	indicating	that	they	are	reaching	the	cell	surface	and	are	capable	of	binding	hormone	and	coupling	to	signaling	partners.		We	have	observed	a	subtle	difference	in	downstream	PKA	targets	between	the	mutant	and	wild	type	hFSHR,	suggesting	that	there	might	be	a	
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difference	in	the	ability	to	activate	downstream	targets.	Studying	the	interaction	between	hFSHR	and	caveolin	has	the	potential	to	develop	new	contraceptive	antagonists	and	alternative	agonists	to	regulate	fertility.						 																					
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Introduction:			 The	ability	of	all	living	organisms	to	receive	and	respond	to	external	stimuli	is	essential	for	survival.	These	processes	are	regulated	by	cell	surface	receptors	including	g	protein-coupled	receptors	(GPCRs).	GPCRs	account	for	over	800	types	of	receptors	and	are	the	largest	set	of	drug	targets	in	the	pharmaceutical	market,	thus	signifying	the	importance	of	their	study	in	greater	detail.1	The	human	follicle	stimulating	hormone	receptor	(hFSHR)	is	a	glycoprotein	hormone	GPCR	important	in	both	male	and	female	reproductive	processes.2	hFSHR	is	expressed	on	the	granulosa	cells	of	the	ovary	in	females,	and	the	sertoli	cells	of	the	testis	in	males.	When	activated	with	human	follitropin	from	the	anterior	pituitary,	hFSHR	induces	a	signal	transduction	pathway	leading	to	follicular	maturation	in	females	and	sperm	production	in	males.2			
Follitropin	signaling:		 Follitropin	is	released	by	the	gonadotrope	cells	of	the	anterior	pituitary	in	response	to	gonadotropin	releasing	hormone	(GnRH).2	GnRH	is	released	from	the	hypothalamus	in	pulses	based	on	gonadal	steroid	signaling.3	GnRH	travels	through	the	hypophyseal	portal	to	the	anterior	pituitary	stimulating	the	production	of	lutenizing	hormone	and	follitropin.	Slow	GnRH	pulses	stimulate	the	production	and	secretion	of	follitropin	in	gonadotrope	cells.4	Follitropin	is	then	released	into	the	blood	stream.	In	order	for	the	signal	to	be	received	successfully,	follitropin	must	bind	successfully	to	its	GPCR,	FSHR.1		
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Figure	1.	Diagram	Illustrating	Hypogonadal	Axis5		 FSHR	belongs	to	the	glycoprotein	family	of	hormone	receptors	(GPHRs).	Similar	to	other	GPCRs,	the	protein	crosses	the	membrane	seven	times	as	α-helices	with	a	super-secondary	structure	of	α-turn-α	in	three	intracellular	loops	(IL)	and	three	Extracellular	loops	(EL).6		
 
Figure	2.	Human	Follicle	Stimulating	Hormone	
Receptor	
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	 The	transmembrane	domain	is	highly	conserved	within	the	GPHR	class.	The	receptor	has	three	primary	domains:	Ectodomain,	transmembrane	domain	and	endodomain.	The	ectodomain	is	composed	of	two	significant	subdomains,	the	hormone	binding	subdomain	and	the	signal	specificity	binding	domain.	Within	the	hormone-binding	domain	there	are	12	lecuine	rich	repeats	and	other	hydrophobic	residues	giving	it	a	cylindrical-horseshoe	shape.5	The	hormone-binding	domain	possesses	β-sheets,	complementary	to	follitropin,	allowing	it	to	interact	electrostatically.			 The	hinge	region	of	the	binding	domain	contains	three	critical	disulfide	bonds	that	
communicate	a	conformational	change	through	the	transmembrane	domain	upon	the	binding	of	follitropin.	As	follitropin	binds	to	the	hormone-binding	domain,	a	conformational	change	in	the	signal	molecule	is	believed	to	take	place	exposing	a	pocket	within	the	follitropin.	This	pocket	is	specific	for	a	sulfated	tyrosine	that	lies	on	the	hinge	region.	As	residues	on	follitropin	stabilize	the	sulfated	tyrosine,	a	conformational	change	in	the	receptor	occurs,	which	is	communicated	through	the	transmembrane	domain	into	the	endodomain.5		
Figure	3.	Molecular	structure	FSHR6	
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	Figure	4.	Signal	transduction	of	
FSHR6	
 	 It	is	believed	that	this	conformational	change	on	the	C-terminus	(intracellular	side)	of	the	GPCR	causes	a	conformational	change	in	the	attached	Gsα-subunit.	This	structural	change	causes	the	subunit	to	favor	the	release	of	GDP	and	uptake	of	GTP,	which	activates	the	G-protein.	Gsα	stimulates	the	activity	of	adenyl	cyclase,	which	converts	ATP	cyclic	adenosine	monophostophate	(cAMP).7	cAMP	then	activates	protein	kinase	A	(PKA),	which	phosphorylates	cAMP	response	element	binding	protein	(CREB).	CREB	is	a	transcription	factor	that	will	then	act	to	stimulate	steroidogenesis,	which	is	involved	in	the	aforementioned	processes	of	sex	cell	maturation.		
 
Figure	5.	Downstream	signaling	of	FSHR		 There	are	many	components	within	the	plasma	membrane	that	are	required	for	appropriate	signal	transduction,	and	appropriate	activation	of	secondary	messengers.		
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However,	these	components	are	expressed	at	relatively	low	levels	along	the	surface.	Given	this	low	density,	it	would	be	nearly	impossible	for	these	components	to	randomly	associate	at	the	correct	time	to	transduce	a	signal.	Yet	somehow,	this	signaling	occurs	rapidly	and	efficiently.		
Plasma	membrane	&	Lipid	Rafts:		 One	possible	mechanism	for	the	efficient	transduction	of	signal	is	that	these	components	co-localize	in	a	sub-domain	of	the	plasma	membrane	referred	to	as	lipid	rafts.	All	cells	are	separated	from	their	surroundings	by	a	plasma	membrane.	This	membrane	is	semipermeable	to	certain	ions,	and	small	organic	molecules,	and	controls	the	migration	of	larger	molecules	moving	in	to	and	out	of	the	cell.	Plasma	membranes	are	composed	of	a	lipid	bilayer	studded	with	various	proteins.	The	lipid	bilayer	consists	of	hydrophobic	acyl	chains	with	a	polar	head	group.	In	an	aqueous	environment,	the	hydrophobic	head	groups	are	exposed	to	the	surroundings	and	interior	of	the	cell,	while	the	acyl	chains	lay	within	the	membrane	itself.			 Based	on	the	fluid	mosaic	model,	the	lipid	bilayer	functions	as	a	two-dimensional	liquid.8	According	to	this	model,	individual	proteins	and	acyl	chains	are	able	to	move	relatively	freely	within	the	membrane.	However,	there	is	a	certain	fluidity/permeability	balance	that	must	be	met	for	the	cell	to	function.	Because	some	of	the	acyl	chains	possess	double	bonds,	there	are	often	openings	within	the	membrane	itself.7	The	addition	of	cholesterol	into	the	plasma	membrane	allows	these	gaps	to	close,	and	limit	the	permeability	and	fluidity	of	the	cell.	The	intercalation	of	cholesterol	at	higher	concentrations	can	also	produce	micro-domains	known	as	lipid	rafts.9			
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Figure	6.	Intercalation	of	cholesterol	in	plasma	membrane10									 These	sub-domains	are	characterized	by	a	higher	concentration	of	sphingolipids	and	high	levels	of	cholesterol,	allowing	the	acyl	chains	to	pack	more	densely.8	Lipid	rafts	are	expressed	in	a	wide	variety	of	cells,	however,	a	certain	subset	of	those	cells	also	express	the	protein,	caveolin.		
Caveolin:		 Caveolin	is	a	21	kD,	structural	membrane	protein.	The	presence	of	caveolin	in	the	membrane	causes	a	50-100	nm	invagination	of	the	lipid	raft	membrane,	referred	to	as	caveolae.9	It	has	been	demonstrated	in	literature	that	these	domains	enable	spatial	co-localization	of	interacting	proteins	to	promote	efficiency	of	signal	transduction.11	Caveolae	are	primarily	found	in	muscle	cells,	endothelial	cells,	and	adipocytes.		
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Figure	7.	Caveolin	promote	formation	of	caveolae12		 There	are	three	isoforms	of	caveolin	found	in	mammalian	cells,	caveolin-1,	caveolin-2,	&	caveolin-3.	All	three	proteins	express	a	similar	conformational	structure	with	a	cytoplasmic	C	&	N	terminus	with	a	hairpin	loop	transmembrane	domain,	however,	they	differ	in	which	tissues	they	are	expressed	in.9	For	example,	caveolin-3	is	exclusively	expressed	in	skeletal	and	cardiac	myocytes.	Caveolin-1,	the	predominant	form,	tends	to	dictate	caveolae	formation	through	oligomerization.		Caveolin	has	three	major	functions	when	it	comes	to	the	formation	of	lipid	rafts	and	signal	transduction.	Primarily,	it	is	involved	with	forming	the	flask	like	invaginations	within	the	membrane	of	the	cell.	It	does	this	by	essentially	reducing	the	physical	strain	caused	by	the	curvature	of	the	membrane.13	Caveolin	also	acts	as	a	scaffolding	protein.	It	has	the	ability	to	recruit	specific	proteins	to	localize	within	the	caveolae.	Finally,	caveolin	acts	as	a	protein	chaperone,	and	assists	with	cell	membrane	trafficking.	Within	caveolin	itself,	subdomains	exist	to	carry	out	these	various	processes.	An	example	of	this	is	the	scaffolding	domain	of	caveolin	(CSD).9	This	string	of	amino	acids	acts	to	anchor	necessary	signaling	molecules	for	efficient	signal	transduction.	The	proteins	that	co-localize	with	caveolin	
	 12	
express	a	sequence	of	amino	acids	that	interact	with	the	CSD	referred	to	as	the	caveolin-binding	motif	(CBM).	 	These	short	amino	acid	chains	are	hydrophobic	and	rich	in	aromatic	residues.	The	typical	sequences	are	ϕxϕxxxxϕ	or	ϕxxxxϕxxϕ	or	combined	sequence	ϕxϕxxxxϕxxϕ,	where	ϕ	is	a	phenylalanine,	tyrosine	or	tryptophan	residue,	and	x	can	be	any	amino	acid.14	It	has	been	established	that	hFSHR	expresses	the	CBM	sequence	of	amino	acids	between	residues	between	479	&	
489	with	each	aromatic	residue	being	a	phenylalanine.		
	 					Caveolin	Binding	Motif		 		Ф		X		Ф		X		X		X		X		Ф		X		X		Ф			 479			481																	486								489			 In	order	to	further	investigate	caveolin-hFSHR	interactions,	we	have	set	out	to	establish	stable	mutant	cell	lines	that	express	different	combinations	of	mutations	in	each	of	the	phenylalanine	locations.	Previous	research	in	the	Cohen	lab	has	generated	transiently	transfected	mutants	of	the	caveolin	binding	motif,	but	none	that	readily	express	the	mutated	receptor	organically.	Our	research	represents	the	investigation	of	an	F479L	polymorphism.	By	evaluating	behavior	of	the	mutated	domain	we	can	better	understand	the	relationship	between	hFSHR	and	lipid	rafts.	As	the	interaction	is	better	comprehended,	
Figure	8.	Caveolin	scaffolding	domain	schematic15	
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research	can	be	focused	on	the	implications	of	this	interaction	in	infertility	and	birth	control.		
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Methods:	
Cell	Culture: Human	Embryonic	Kidney	cells	293	(HEK293)	were	grown	in	culture	at	37°C	in	DMEM	with	10%	fetal	bovine	serum	and	penicillin	&	streptomycin.	Cells	were	transfected	with	either	wild	type	hFSHR	DNA	or	mutant	hFSHR	F479L	using	SatisFection.	 
 
DNA	Stable	Transfection: At	75%	confluence,	HEK293	cells	were	transfected	using	SatisFection	reagent.	Cells	were	then	cultured	in	G418	antibiotic	to	select	for	lines	expressing	mutated	(F479L)	receptor	or	wild	type.	After	several	days,	colonies	of	surviving	cells	were	collected	and	plated	in	a	96	well	dish.	Those	that	continued	to	proliferate	were	then	transferred	to	a	12	well	and	then	to	a	6	well,	and	finally	transferred	to	a	T25	and	a	T75	flask	as	they	reached	confluence.	For	more	details	refer	to	Satisfection	Transfection	Reagent	manual	in	Appendix	B. 
 
SDS-PAGE	Western	Blot	Hormone	Treatment: Upon	T75	confluence,	both	HEK293	WT	and	F479L	mutant	cells	were	treated	with	2000	ng	of	FSH	for	either	zero,	five,	15,	or	30	minutes.	The	cells	were	then	lysed	and	protein	contents	evaluated	by	gel	electrophoresis	using	7.5%	acrylamide	gel.	The	proteins	were	then	transferred	to	a	PVDF	membrane	using	a	semi-dry	electrophoresis	method	and	blocked	with	5%	milk	in	TBST.	The	membranes	were	then	probed	with	Anti-hFSHR	mAb	106.105	(105)	for	hFSHR;	P-p44/42	MAPK	Rabbit	Ab	for	phosphorylated	p44;	and	P-PKA	substrates	for	downstream	signaling	targets	of	P-PKA.	Membranes	were	then	probed	with	anti-mouse	secondary	antibody	for	105	and	anti-rabbit	for	P-p44	and	P-PKA	substrates.	Membranes	were	imaged	(BIORAD	ChemiDoc	MP	Imaging	System).	For	more	detailed	procedures	refer	to	Appendix	C.	 
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Immunofluorescence	Microscopy:	 HEK	293	WT	and	F479L	mutant	were	grown	on	glass	coverslips	and	fixed	using	a	4%	paraformaldehyde	PBS	solution.	Cells	were	probed	for	hFSHR	using	mAb	106.105.	Goat	anti-mouse	with	an	alexa-red	fluorophore	was	used	as	a	secondary	antibody.	Slides	were	then	evaluated	on	fluorescent	microscope	(Olympus	BX60). 
 
Discontinuous	Sucrose	Gradient 2	T75s	of	each	HEK	293	WT	and	F479L	were	grown	to	80%	confluence.	One	T75	of	each	was	treated	with	2000	ng	of	FSH,	incubated	for	30	minutes.	Cells	were	collected	and	resuspended	in	0.5	M	sodium	carbonate	(pH	11)	and	incubated	for	20	minutes.	Cells	were	then	dounced	and	sonicated.	Lysates	were	added	to	90%	sucrose	in	1:1	dilution	and	added	to	ultracentrifuge	tube.	A	35%	solution	followed	by	a	5%	solution	were	laid	on	top.	Ultracentrifuge	(Beckman	L-70)	was	run	at	34,000	RPM	for	16	hours.	Fractions	from	the	gradient	were	recovered	and	analyzed	using	SDS-PAGE	and	Western	Blot.	Gel	electrophoresis	was	carried	out	using	7.5%	acrylamide	gel.	Proteins	were	then	transferred	to	a	PVDF	membrane	using	a	semi-wet	electrophoresis	method	and	blocked	with	5%	milk	in	TBST.	The	membranes	were	then	probed	with	Anti-hFSHR	mAb	106.105	(105)	for	hFSHR.		Membranes	were	then	probed	with	anti-mouse	secondary	antibody	for	105.	Membranes	were	imaged	(BIORAD	ChemiDoc	MP	Imaging	System). 
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Results:	
	 Establishment	of	a	stable	hFSHR-F479L	expressing	cell	line	After	HEK293	cells	were	transfected	with	F479L	SatisFection	vector,	colonies	were	harvested	and	receptor	expression	were	evaluated	(See	Methods:	DNA	Stable	Transfection	for	details).	Colonies	were	then	labeled	A-F	and	evaluated	using	SDS-PAGE/Western	Blot.	Membranes	were	probed	with	anti-hFSHR	mAb	106.105	(Figure	10).	
	
Figure	9.	Figure	1.	Western	blot	of	protein	lysates	from	HEK	293	cell	lines	stably	transfected	with	hFSHR-479L	
mutant	(Lanes	A-F).	Lane	WT	is	control	HEK	293	cell	line	stably	expressing	wild	type	receptor.	hFSHR	probed	
with	anti-hFSHR	mAb	106.105.	Mutant	cell	line	from	lane	E	was	used	to	carry	out	subsequent	experiments.		There	is	a	single	band	at	80	kD	seen	in	Lanes	A-F	of	similar	intensity.	There	is	also	a	darker	band	in	the	WT	lane	at	80	kD	along	with	a	faint	band	around	50	kD	mark.			
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Does	hFSHR-F479L	Localize	on	the	Cell	Surface	Similar	to	Wild	Type	Receptor?	HEK293-hFSHR	F479L	(Mutant)	were	compared	to	HEK293-hFSHR	(WT)	using	immunofluorescence.		
	
Figure	10.	Immunofluorescence	of	HEK	293	cells	stably	expressing	hFSHR	isoforms	as	indicated.	A	&	B-	Wild	Type	
hFSHR,	C	&	D-	hFSHR-F479L	mutant.		The	top	row	of	Figure	10,	labeled	WT,	represents	the	HEK293-hFSHR	wild	type	cells	and	the	bottom	row	represents	the	F479L	mutant.	A	and	C	represent	cells	that	were	not	treated	with	106.105	antibody	and	serve	as	a	negative	control.	In	B	and	D	there	is	increased	fluorescence	around	the	perimeter	of	the	cell	indicating	that	both	the	wild	type	and	mutant	receptor	are	localizing	in	the	cell	membrane.		
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Does	the	Mutated	Receptor	Localize	in	Lipid	Rafts?		 To	investigate	the	localization	of	the	mutated	receptor	in	lipid	rafts,	a	discontinuous	sucrose	gradient	followed	by	SDS-PAGE	Western	blot	was	carried	out	(See	methods	for	detailed	procedures).	The	results	of	the	Western	Blot	can	be	seen	below.	
	
Figure	11.	Figure	3.	Western	blot	of	protein	lysates	from	HEK	293	cell	lines	expressing	wild	type	hFSHR	or	hFSHR-
F479L.	Cells	were	treated	for	30	min	with	20ng/ml	hFSH	followed	by	separation	on	a	discontinuous	sucrose	
gradient.	Collected	fractions	were	probed	for	hFSHR	using	mAb	106.105.	Lipid	rafts	are	predicted	to	be	seen	in	
fractions	5,	6,	7.		 The	red	box	indicates	where	the	fractions	from	the	sucrose	gradient	where	lipid	rafts	may	be	present.	It	is	apparent	that	there	is	receptor	present	within	the	lipid	rafts	in	both	the	wild	type	and	F479L	mutant.		
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Does	a	Mutation	in	the	Caveolin	Binding	Motif	Affect	Downstream	Signal	Transduction?		 F479L	and	wild	type	were	treated	with	FSH	for	0,	5,	15,	or	30	minutes.	Cells	were	then	lysed	and	analyzed	via	Western	Blot.	Membranes	were	then	probed	for	phosphorylated	PKA	substrates	and	phospho-P44	MAPK.	The	results	of	these	blots	can	be	seen	below.		
	
Figure	12.	Figure	4.	Western	blot	of	protein	lysates	from	HEK	293	cell	lines	expressing	wild	type	hFSHR	or	hFSHR-
F479L.	Probed	for	hFSHR,	p44-MAPK	(top),	and	PKA	Substrates	(bottom).	★-	indicates	bands	that	are	different	
between	the	cell	lines	for	PKA	substrates	
 Based on the above blot probed for P44-MAPK, similar density bands can be 
observed between wild type and mutant. This indicates that P44-MAPK signaling seems 
to be conserved. On the other hand, there are several differences between wild type and 
mutant in downstream PKA substrates. These differences are noted by stars on the right 
side of Figure 12. These differences indicate that there may be slight differences in 
downstream PKA signaling. 
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Discussion:	
	 There	were	two	main	phases	to	the	experiments	carried	out	to	investigate	F479L	mutant	receptor.	The	first	phase,	was	first	to	create	a	cell	line	that	is	stably	expressing	the	F479L	mutation	in	the	hFSHR.	The	second	phase,	was	to	investigate	the	raft	residency,	function,	and	consequential/downstream	signaling	of	the	mutated	receptor,	and	compare	it	to	the	wild	type	receptor.		 Previous	work	in	our	lab	has	investigated	a	transient	or	temporary	transfection	of	the	F479L	mutant.16	Here,	we	used	a	stable	transfection	method	to	better	simulate	in	vivo	mechanisms.	Also,	by	establishing	a	cell	line	that	is	stably	expressing	the	F479L	receptor,	future	experimentation	can	be	carried	out	more	efficiently.	After	HEK293	F479L	colonies	were	established,	cells	were	lysed	and	evaluated	for	presence	of	hFSHR	using	a	Western	Blot.	The	results	of	this	experiment	can	be	seen	in	figure	9.	Here	it	can	be	noted	that	receptors	are	present	in	each	of	the	mutant	colonies	established,	as	well	as	the	wild	type	cells.	For	the	purposes	of	consistency,	we	used	cell	line	E	for	future	experimentation.	Within	this	figure,	it	is	also	important	to	note	within	the	wild	type	lane	the	presence	of	a	second	band	approximately	20	kD	below	the	receptor.	It	is	thought	that	this	band	may	be	a	potential	glycosylation	variant	of	the	wild	type	receptor.	It	is	also	important	to	note	that	this	variant	is	barely	visible	within	the	mutant	lanes.			 Past	research	has	demonstrated	that	the	glycosylation	of	hFSHR	occurs	at	four	different	sites	within	the	extracellular	domain.	Although	it	has	been	shown	that	glycosylation	is	not	directly	necessary	for	hormone	binding,	certain	sites	are	required	for	proper	conformational	folding	in	order	for	receptor	to	properly	bind	to	hormone.	17		 The	second	phase	of	our	experiment	investigated	the	localization	and	function	of	the	mutated	receptor.	First,	we	used	immunofluorescence	to	establish	that	the	receptor	was	
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residing	within	the	cell	membrane.	The	results	of	this	experiment	can	be	seen	in	Figure	10A-D.	Figure	10A	and	10C	served	as	our	negative	control,	and	were	therefore	not	treated	with	primary	antibody.	This	was	done	to	negate	any	effects	of	auto-fluorescence	or	background	fluorescence.	The	presence	of	red	fluorescence	around	the	perimeter	of	the	cells	in	both	the	wild	type	and	F479L	mutant	is	indicative	of	the	localization	of	receptor	within	cell	membrane.	It	is	not	quantifiable	because	this	was	done	using	indirect	immunofluorescence.	However,	we	can	conclude	that	receptors	are	present	within	the	cell	membrane	in	both	wild	type	and	mutant.			 It	is	believed,	that	within	the	cell	membrane	there	lies	a	region	of	higher	buoyancy	designated	as	lipid	rafts.	Next,	we	set	out	to	examine	if	the	mutated	receptor	localizes	within	these	domains	similarly	to	the	wild	type.	To	do	this	we	performed	a	discontinuous	sucrose	gradient	followed	by	a	Western	Blot	analysis.	The	results	of	this	experiment	can	be	seen	in	Figure	11.	In	the	wild	type	analysis,	receptors	can	be	seen	localizing	within	the	lipid	raft	region	of	the	sucrose	gradient	indicated	by	the	red	box.	However,	receptors	can	also	be	seen	in	later	or	denser	fractions.	There	are	several	reasons	this	may	be	the	case.	As	discussed	earlier,	there	are	glycosylation	variants	of	the	wild	type	receptor.	This	glycosylation	may	occur	at	different	stages.	Glycosylation	can	occur	in	the	endoplasmic	reticulum	and	within	the	golgi	apparatus.	Enzymatic	glycosylation	can	also	occur	while	the	protein	is	being	transported	to	the	cell	surface.	These	bands	may	be	indicative	of	"immature"	receptor	in	different	stages.			 Within	the	F479L	assay,	receptor	can	also	be	seen	present	within	the	lipid	raft	fractions	of	the	sucrose	gradient.	However,	expression	is	greatly	reduced.	Perhaps	this	is	a	result	of	an	interruption	of	the	caveolin-binding	motif.	A	disruption	of	this	domain	could	potentially	disturb	the	co-localization	with	caveolin	and	may	down	regulate	the	amount	of	
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receptor	localizing	within	lipid	rafts.	It	is	also	important	to	note	that	unlike	the	wild	type,	receptor	does	not	seem	to	be	present	in	denser	sucrose	fractions.			 Our	last	experiments	focused	on	downstream	signaling	of	receptors	to	determine	if	the	mutation	had	an	impact	of	consequential	signaling.	As	seen	in	figure	5,	there	are	two	primary	signal	transduction	pathways	that	are	activated	as	a	result	of	FSH	binding	to	receptors.	The	first	pathway	we	examined	was	the	Arrestin/p44	MAPK	pathway.	This	was	done	by	treating	the	cells	with	hormone	for	varying	lengths	of	time,	lysing	the	cells,	and	analyzing	via	Western	Blot.	The	results	of	this	can	be	seen	in	Figure	12.	First,	membranes	were	probed	with	anti-hFSHR	mAb	106.105.	Within	the	wildtype	membrane	it	can	be	seen	that	more	receptor	seems	to	be	recruited	with	the	addition	of	hormone	although	this	mechanism	has	yet	to	be	investigated.	On	the	other	hand,	this	did	not	occur	within	the	mutant.	The	membranes	were	also	probed	with	anti-phospho-p44/MAPK.	Here	it	can	be	seen	that	signaling	seems	to	be	conserved	in	the	mutant	relative	to	the	wild	type.	Although	the	amount	of	receptor	seen	at	5	and	15	minutes	in	the	wild	type	increased,	it	is	also	important	to	note	that	the	expression	of	the	secondary	messenger	p44/MAPK	seems	to	be	conserved	between	wild	type	and	mutant.	This	has	also	been	demonstrated	in	the	work	of	Stanley	Soroka	'16.	Although	Soroka's	experiments	used	a	transient	transfection	technique,	it	can	be	seen	in	Appendix	A	that	p44/MAPK	signaling	was	also	conserved	with	the	F479L	mutant.	Therefore,	it	can	be	concluded	that	the	F479L	mutation	does	not	affect	the	arrestin-P44/MAPK	pathway.		 The	other	pathway	that	hFSHR	activates	is	the	Gsα-PKA	pathway	seen	in	Figure	5.	Here,	membranes	were	probed	with	a	downstream	PKA	substrates	antibody.	Unlike	the	p44-MAPK	pathway,	it	seems	there	are	slight	variations	in	downstream	signaling	within	this	pathway.	One	potential	mechanism	for	this	could	be	the	idea	that	free	caveolin-1	
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within	the	cell	can	inhibit	PKA	signaling.	Expression	of	activated	CREB	was	noted	to	drastically	decrease	with	presence	of	cav-1	in	vitro.17	Therefore,	by	disrupting	the	CBM-CSD	interaction,	more	caveolin	may	be	present	within	the	cytoplasm	yielding	down	regulation	of	PKA	substrate	activation.	On	the	other	hand,	although	it	has	been	shown	that	caveolin	also	interacts	with	MAPK,	there	did	not	seem	to	be	a	difference	in	signaling	in	our	experiments.			 For	future	investigation	it	would	be	important	to	examine	certain	components	of	the	experiments	carried	out	here.	For	example,	these	experiments	were	done	under	the	assumption	that	a	mutation	within	the	transmembrane	domain	of	the	receptor	will	not	affect	the	hormone-binding	region.	Therefore,	we	assumed	that	hormone	would	bind	equally	between	the	wild	type	receptor	and	mutated	receptor.	If	untrue,	this	would	result	in	altered	consequential	signaling	between	receptors.	Another	assumption	made	for	this	study	was	that	the	levels	of	caveolin-1	and	caveolin-2	in	HEK293	cells	are	similar	to	that	of	Sertoli	or	granulosa	cells.	Because	caveolin	plays	such	a	dynamic	role	in	the	localization	of	hFSHR	and	its	downstream	elements,	lower	or	higher	levels	of	caveolin	could	drastically	change	this	dynamic,	and	consequentially	affect	results	seen	here.	Furthermore,	caveolin	expression	and	co-localization	with	receptor	should	also	be	investigated	to	determine	if	there	is	decreased	co-localization	with	the	mutated	receptor.	This	could	be	done	using	immunofluorescence	or	discontinuous	sucrose	gradient	assay	followed	by	Western	Blot	analysis.	Effects	of	F481L,	F486L,	and	F489L	mutations	should	also	be	investigated.	Based	on	previous	work,	it	has	been	established	that	the	F481	lies	in	an	opposite	direction	of	the	other	aromatic	residues	as	seen	in	Figure	13.				
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Figure	13.	A	view	of	transmembrane	domain	IV,	the	caveolin	binding	motif,	of	hFSHR.	Demonstrates	the	alpha	
helix	from	intracellular	to	extracellular	domain.		 On	the	other	hand,	F479,	F481,	and	F486	come	before	the	P487	residue,	which	interrupts	the	helix.	In	this	case,	the	F489	residue	may	have	the	least	effect	on	the	CBM-CSD	interaction.	Further	experimentation	is	required	to	elucidate	the	dimensional	mechanisms	of	the	CBM-CSD	interaction.	Once	these	single	mutations	have	been	investigated,	combinations	of	these	mutations	should	be	examined	to	determine	if	any	of	them	have	a	greater	role	in	the	disruption	of	this	interaction.			 Disruption	of	the	interaction	of	caveolin	with	hFSHR	could	potentially	interrupt	reproductive	signals	of	the	HPG	axis.	By	interrupting	these	signals	without	impacting	hormone	levels,	contraception	could	be	achieved	without	the	negative	implications	of	birth	control.		
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Appendix	A:	Soroka	'16	Western	Blot	of	transient	transfected	hFSHR	variants	
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Appendix	B:	Satisfection	Transfection	Reagent	
	
	
SatisFection Transfection Reagent		
MATERIALS PROVIDED		 	 	 Quantitya	 	
Materials provided	 Catalog #204121	 Catalog #204122	 Catalog #204123	
	 	 	 	
SatisFection Transfection Reagent	 0.3 ml	 0.75 ml	 2 × 0.75 ml	
	 	 	 		
a The reagent has been optimized for 625–1250 transfections per 0.75 ml transfection reagent using 24-well 
tissue culture dishes. 	
STORAGE CONDITIONS		
SatisFection Transfection Reagent: 4°C		
ADDITIONAL MATERIALS REQUIRED		
Media for preparing transfection mixture (Opti-MEM, DMEM, RPMI or other cell culture media		
without serum and antibiotics)		
Media for cell growth (Opti-MEM, DMEM, RPMI, or other cell culture media, including serum, 
growth factors, and antibiotics if appropriate)			
Revision B	 © Agilent Technologies, Inc. 2010.												
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INTRODUCTION		
Gene transfection into eukaryotic cells is a fundamental tool for analysis of 
gene function and for production of recombinant gene products. 
SatisFection Transfection Reagent gives optimal efficiencies and protein 
expression levels in common cell lines, while significantly improving 
efficiencies in many hard-to-transfect and primary cells. Maximum gene 
expression and protein production is observed 36–72 hours post-
transfection.		
The SatisFection reagent is a novel cationic polymer suitable for both 
transient and stable transfections in the presence or absence of serum. This 
polymer functions by binding and condensing DNA into a polyplex that 
enters the cell via endocytosis. Properties of the polyplex facilitate both 
endosomal rupture and protection of the bound DNA from lysosomal 
degradation. Continued exposure to cellular pH ultimately reduces the 
polymer into a non-toxic monomer. The monomer is then easily excreted 
from the cellular compartment, resulting in lowest the levels of cytotoxicity 
and increased cell viability. As a result, the SatisFection reagent is ideal for 
experiments that require large, healthy populations of positively transfected 
cells for downstream applications, e.g., signal transduction pathway 
analysis.		
PREPROTOCOL CONSIDERATIONS		
The protocol provided below will allow effective transfections for most cell 
types, however, optimal transfection conditions may vary. The following 
parameters should be established for each cell line and plasmid used.		
DNA Quality and Concentration		
The use of highly purified DNA is critical for successful transfection. 
Suitable quality DNA is obtained using StrataPrep plasmid miniprep kit, or 
by cesium chloride purification. The optimal concentration for transfection 
generally falls within the range of 0.4–1.0 µg DNA per well of a 24-well 
plate, with 0.6 µg as the recommended starting point for optimization.		
Cell Density		
While we recommend a cell density of 60–80% confluence after 18–24 
hours of incubation at the time of transfection for most cell types, the 
optimal cell density should be determined specifically for each cell type.		
Reagent to DNA Ratio		
The optimal reagent to DNA ratio should allow the highest transfection 
efficiencies with the lowest level of toxicity. This is usually achieved within 
the range of 1–2 µl reagent per µg DNA, with 1.5 µl reagent per µg DNA 
the recommended starting point for optimization.		
Transfection Incubation Time		
The optimal time that the transfection reagent is in contact with the cells 
should be determined by testing a range of incubation times from 36–72 
hours.		
2	 SatisFection Transfection Reagent	
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SATISFECTION TRANSFECTION REAGENT VOLUME GUIDELINES		
The following procedure for the generation of transfectants uses a 24-well 
tissue culture plate. The optimal ratio of SatisFection transfection reagent to 
DNA must be determined for each plasmid and cell line, however 1.5 µ1 
reagent per 1 µg DNA is the recommended starting point for optimization. 
Reagent volumes for cells not cultured in 24-well tissue culture plates are 
given in Table I. When preparing the transfection mixture, the volume of the 
transfection mixture may be scaled up by increasing the components 
proportionally to accommodate several transfections.		
TABLE I		
SatisFection Transfection Reagent use for Various Cell Culture Dish Formats a			 	 	 DNA solution per well	 Transfection reagent per well	 	 	
	 	 	 	 	 	 	 	 		 	 	 	 	 Volume of	 	 	 		 	 	 	 Final volume	 transfection	 Final volume of	 	 		 	 	 	 of DNA	 reagent stock	 transfection	 Total	 	
Tissue	 	 Recommended	 	 solution	 solution (µl)	 reagent	 volume of	
culture	 Diameter	 number of	 Amount	 diluted with	 [1.5:1 ratio	 solution diluted	 transfection	
dish	 of the well	 adherent cells	 of DNA	 serum-free	 (µl reagent:	 with serum-free	 mixture plus	
format	 (mm)	 (×105)	 (µg)	 medium (µl)	 µg DNA)]	 medium (µl)	 medium (µl)	
96-well	 6.4	 0.04–0.1	 0.15	 7.5	 0.225	 7.5	 15	µl	
	 	 	 	 	 	 	 	 	
48-well	 10	 0.1–0.3	 0.3	 15	 0.45	 15	 30	µl	
	 	 	 	 	 	 	 	 	
24-well	 15	 0.27–0.67	 0.6	 30	 0.9	 30	 60	µl	
	 	 	 	 	 	 	 	 	
12-well	 22	 0.6–1.5	 1	 50	 1.5	 50	 100	µl	
	 	 	 	 	 	 	 	 	
6-well	 35	 1.5–3.7	 2	 100	 3	 100	 200	µl	
	 	 	 	 	 	 	 	 	
35-mm	 35	 1.5–3.7	 2	 100	 3	 100	 200	µl	
	 	 	 	 	 	 	 	 	
60-mm	 60	 4.0–11.0	 6	 300	 9	 300	 600	µl	
	 	 	 	 	 	 	 	 	
100-mm	 100	 12.0–31.0	 16	 800	 24	 800	 1600	µl	
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SatisFection Transfection Reagent		
Catalog #204121, 204122, and 204123		
QUICK-REFERENCE PROTOCOL–ADHERENT CELLS		
Seed cells to 2.7–6.7 × 104 cells per well of a 24-well plate and incubate 18–24 
hours so that cells are at 60–80% confluency at time of transfection		
Prepare transfection mixture		
♦ Pipet 30 µl antibiotic-free, serum-free medium (room temperature) into 
microcentrifuge tube. Pipet reagent (0.9 µl) into medium, do not touch plastic. 
♦ Pipet 30 µl antibiotic-free, serum-free medium (room temperature) into separate 
microcentrifuge tube. Add DNA (0.6 µg) to medium. 
♦ Add the diluted transfection reagent dropwise to the diluted DNA while gently 
vortexing or mixing with the pipet tip.  
♦ Incubate transfection mixture 15 minutes at room temperature. 	
Add the transfection mixture to the cells		
♦ Add transfection mixture dropwise and incubate for 36–72 hours under standard 
growth conditions. 	
Perform stable transfection (optional)		
♦ 36–72 hours after the transfection (above), split cells (1:5 suggested).  
♦ After 24 hours, apply selection antibiotics.  
♦ Continue selection, replacing medium every 4–7 days until colonies form. 
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Appendix	C:	Protein	Extraction	and	Western	Blot		
Protein Extraction Protocol 
1) Do all steps on ice or at 4o. 
 
2) Rinse cells with 1X PBS (1 ml, ice cold) 
 
3) Add 0.5 ml lysis buffer/well 
 
4) Incubate on ice for 20 min. 
 
5) Scrape into microfuge tube 
 
6) Transfer extract to Dounce homogenizer and homogenize with 10 strokes of Dounce 
homogenizer (tight pestle) 
 
7) Transfer extract back to microfuge tube 
 
8) Spin in microfuge in cold room for 10 min at max speed  
 
9) Transfer supernatant to new tube.  Save pellet. 
 
 
Igepal-DOC lysis buffer    
1% Igepal     
0.4% deoxycholate 
10mM Tris pH7. 
6.6mM EDTA 
 
-add 1X protease inhibitor cocktail before using lysis buffer 
 
SDS polyacrylamide gel electrophoresis and Western Blot 
 
 
 
 
 
 
 
 
 
 
	 32	
Materials 
BCA protein assay (Pierce Biotech, cat. #23225) 
Mini-PROTEAN II gel apparatus (Biorad) 
Costar gel-loading tips (Krackler Scientific, cat. #MN520R-LRS) 
Prestained SDS-Page broadrange molecular weight standard (NEB, cat. #P7708S) 
Trans-blot Semi-Dry Transfer cell (Biorad)        
Immobilon-P membrane (Millipore, cat. #IPV00010) 
heat-sealable bags (Kapak, cat. #TRS-95250) 
Kodak Biomax light autoradiagraphy film, 13 x 18 cm (Perkin Elmer Life Sciences, cat. #868-
9358)  
Radtape (Diversified Biotech, cat. #RAD-10) 
 
Reagents 
TEMED (Sigma) 
Tween-20 (Sigma) 
Price Chopper non-fat dry milk 
Isopropanol (Sigma) 
 
Gel Buffers 
Acrylamide solution (30% acrylamide/0.8% bis-acrylamide) 
-dissolve 30g acrylamide (FW=71.08), 0.8g bis-acrylamide (FW=154.17) in a total 
volume of 100ml water. Filter through 0.2um filter. 
 
4X Running Gel Buffer (1.5M Tris, pH 8.8) 
-dissolve 36.3g Tris Base (FW=121.1) in 150ml water. Adjust to pH 8.8. Add water to 
total volume of 200ml. Filter through 0.2um filter.     
 
4X Stacking Gel Buffer (0.5M Tris, pH 6.8) 
-dissolve 12.1g Tris Base (FW=121.1) in 150ml water. Adjust to pH 6.8. Add water to 
total volume of 200ml. Filter through 0.2um filter. 
 
10% SDS 
 -dissolve 10g SDS (FW=288.38) in a total volume of 100ml water. 
 
10% Ammonium Persulfate 
 -dissolve 1.0g APS (FW=228.2) in a total volume of 10ml water. Store at -20˚C in 50-
100ul aliquots. 
 
1M Tris, pH 6.8 
-dissolve 12.1g Tris Base (FW=121.1) in 80ml water. Adjust to pH 6.8. Add water to 
total volume of 100ml. Filter through 0.2um filter. 
 
 
6X SDS Sample Buffer (0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 0.06% 
bromophenol blue) 
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-combine 3.75ml 1M Tris-Cl, pH 6.8, 6ml glycerol, 1.2g SDS (FW=288.38), 0.93g DTT 
(FW=154.2), 6mg bromophenol blue. Add water to total volume of 10ml. Store at -20˚C in 
0.5ml aliquots. 
2X SDS Sample Buffer (0.125M Tris pH 6.8, 4% SDS, 20% glycerol, 0.2M DTT, 0.02% 
bromophenol blue) 
-combine 2.5ml 4X Tris pH 6.8 (stacking gel buffer), 2ml glycerol, 4ml 10% SDS 
(FW=288.38), 0.31g DTT (FW=154.2), 2mg bromophenol blue. Add water to total volume 
of 10ml. Store at -20˚C in 0.5ml aliquots. 
1X SDS Sample Buffer (0.0625M Tris pH 6.8, 2% SDS, 10% glycerol, 0.1M DTT, 0.01% 
bromophenol blue) 
 
5X Electrophoresis Buffer (0.125M Tris, 0.96M glycine, 0.5% SDS) 
-dissolve 30.3g Tris Base (FW=121.1), 144.1g glycine (FW=75.07), and 10g SDS 
(FW=288.38) in a total volume of 2L water.                                                   
1X Electrophoresis Buffer (0.025M Tris, 0.192M glycine, 0.1% SDS) 
 -add 200ml 5X electrophoresis buffer to 800ml water. 
 
Western Blot Buffers 
Transfer Buffer (0.048M Tris, 0.039M glycine, 20% methanol, 0.00375% SDS)     
-dissolve 11.64g Tris Base (FW=121.1), 5.86g glycine (FW=75.07) in ~1500ml water. 
Add 0.750ml 10% SDS (FW=288.38). Add 400ml methanol. Add water to total volume 
of 2L. No pH adjustment necessary. 
 
10X TBST Wash Buffer (0.1M Tris HCl, 1.5M NaCl, 0.5% Tween-20)         
-dissolve 31.52g Tris HCl (FW=157.6), 175.32g NaCl (FW=58.44) in ~1900ml water. 
Add 10ml       Tween-20. Adjust to pH 7.2.  Add water to total volume of 2L.   
  
 
1X TBST Wash Buffer (0.01M Tris HCl, 0.15M NaCl, 0.05% Tween-20) 
 -add 100ml 10X TBST to 900ml water. 
 
5% milk Blocking Buffer  
-Dissolve 5g milk in a total volume of 100ml 1X TBST.   
 
Method    
1. Determine cell number or protein concentration to be loaded onto gels and what volume to 
load per well.  Note max volumes for different comb configurations.  
 
2. Usually add sample to Tris or PBS and then add sample buffer (2 ul sample + 18 ul PBS + 3.3 
ul 6X sample buffer).  
 
3. Sonicate cells briefly on ice to homogenize.  Purified protein samples do not need to be 
sonicated.  
 
4. Preparing resolving and stacking gels (for BioRad Mini-PROTEAN II): Make sure glass plates 
are clean.  Use Sparkleen or Alconox powder to clean plates.  Rinse with distilled water and then 
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95% EtOH.  Wipe dry with KimWipes.  Select a comb and spacer (ex. 0.75 mm).  Place spacers 
in between the inner and outer glass plates.  Make sure that the spacers are flush with the plates. 
Insert plates into the clamping assembly and tighten screws.  Vacuum grease can be used on the 
casting stand gaskets to prevent buffer leakage.  Snap assembly into the casting stand.  Prepare 
resolving gel.  Pour gel and overlay with 1X Electrophoresis Buffer or isopropanol (use 3.5ml 
resolving gel when using 0.75mm spacers and 7.0ml gel for 1.5mm spacers, this will produce a 
gel approx. 3.25" x 2"). Look for a division between the overlay and resolving gel, this means 
the gel is polymerized.  Pour off overlay, use thin strips of Whatman paper to remove any excess.  
Pour stacking gel and insert comb.  Remove comb when stacking gel is polymerized.  Use a 
syringe and a 12 gauge needle to wash stacking gel wells. Snap clamp assembly into electrode 
assembly.  Vacuum grease can be used on electrode assembly gaskets to prevent buffer leakage. 
 
5. Boil samples 5 minutes at 100°C, and then spin tubes at 13,000rpm for ~1min. in RT micro 
centrifuge. Load samples using Costar Gel-Loading Tips.     
 
6. Place electrode assembly with loaded samples into an electrophoresis chamber. Fill the 
electrode assembly carefully with 1X Electrophoresis Buffer. Fill the electrophoresis chamber 
with 1X Electrophoresis Buffer.  Run gels at 100V for stacking gel, 100-150V for resolving gel 
(can increase to 200V for resolving gel if running on ice). 
   
7. To transfer mini- gels to Immobilon-P membrane using the BioRad Semi-Dry Transfer Cell:  
Remove gels from glass plates. Cut stacking gel away and discard. Incubate gels in Transfer 
Buffer for 20 - 40 min. Cut out 6 pieces of Whatman paper and 1 piece of Immobilon-P 
membrane for each gel that is being transferred. They should be 3.25" x 2". Incubate Immobilon-
P membrane in Methanol for ~10 - 20 seconds. Wet Immobilon-P membrane and Whatman 
paper in Transfer Buffer for 5 - 10 minutes before assembling the gel sandwich according to the 
BioRad Reference Guide. Transfer 1 mini-gel for 15 min. at 15 V, max current.  Transfer 2 mini-
gels for 30 min at 15 V, max current. Make sure that pre-stained MW markers transfer to 
Immobilon-P membrane.   
 
8. Western Blot:   
-Block membrane in 20ml blocking buffer overnight at 4°C or 1h at room temperature on 
rocker in a seal-a-meal bag. 
-Dilute Ab in blocking buffer (1:1000 for serum or 5ug / 10ml for purified Ab). Incubate 
blots with Ab for 1h at rom temperature or overnight at 4°C on rocker in a seal-a-meal 
bag. 
 -Wash blots with 50ml 1X TBST on orbital shaker 3 times, 5 minutes each. 
-Dilute HRP conjugated Ab 1:10,000. Incubate blots with secondary Ab for 1h at room 
temperature or overnight at 4°C on rocker in a seal-a-meal bag.                               
-Wash blots with 50ml 1X TBST on orbital shaker 3 times, 5 minutes each.     
-Add 5ml chemiluminescent substrate to each blot, incubate for 5 minutes. Place blots in 
between transparency film. Push out air bubbles. Develop Western blot. Do a 1 minute 
exposure to check signal intensity. Continue with longer or shorter exposures as needed.   
               (Max. exposure length = 10 min.  Min exposure length = 60 sec.)  
 -For high backgrounds, wash in TBST then re-develop.    
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Resolving Gel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Running Gel: 7.5, 10, or 15% acrylamide, 0.375M Tris-Cl pH 8.8, 0.1% SDS, 0.33% APS, 
0.66% TEMED 
 
                                                             Stacking Gel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stacking Gel: 4% acrylamide, 0.125M Tris-Cl pH 6.8, 0.1% SDS, 0.05%APS, 0.2% 
TEMED 
 
 
 7.5% gel (15ml) 10% gel (15ml) 
15% gel 
(15ml) 
Water 7.5ml 6.25ml 3.75ml 
30% 
acrylamide/ 
0.8% bis-
acrylamide 
3.75ml 5ml 7.5ml 
4X Running 
Buffer 3.75ml 3.75ml 3.75ml 
10% SDS 150ul 150ul 150ul 
10% APS 150ul 150ul 150ul 
TEMED 20ul 20ul 20ul 
 4% gel (10ml) 
Water 6.1ml 
30% acrylamide/ 
0.8% bis-acrylamide 1.3ml 
4X Stacking Buffer 2.5ml 
10% SDS 100ul 
10% APS 100ul 
TEMED 20ul 
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